Indonesian Journal of Cancer Chemoprevention, October 2024
ISSN: 2088–0197
e-ISSN: 2355-8989

Neoadjuvant and Adjuvant Surgical Interventions in Oncology: Optimizing Treatment Pathways

Kirolos Eskandar*

Diakonie Klinik Mosbach, Germany

Abstract

The advancement of cancer treatment has seen significant progress through the integration of neoadjuvant and adjuvant therapies, particularly within the realm of surgical oncology. This literature review follows a systematic approach using PRISMA guidelines, analyzing studies from databases such as PubMed, Google Scholar, Scopus, and Web of Science. The review examines the historical progression, current practices, and future directions of multimodal approaches, focusing on the synergistic benefits of surgery, drug development, targeted therapies, and technological innovations. Neoadjuvant interventions, designed to shrink tumors preoperatively, enhance surgical outcomes by improving resectability, while adjuvant therapies, administered postoperatively, aim to eliminate residual disease and reduce recurrence risk. Findings from clinical trials and case studies highlight improved survival rates, increased tumor resectability, and enhanced patient outcomes through the combination of these therapies. Additionally, the review emphasizes the crucial role of personalized medicine, molecular profiling, and emerging surgical technologies in refining treatment pathways. As the landscape of cancer care evolves, optimizing treatment sequencing and tailoring therapies to individual tumor profiles will be essential for maximizing therapeutic efficacy and improving patient prognosis.

Keywords: *Neoadjuvant Therapy, Adjuvant Surgical Intervention, Surgical Oncology, Multimodal Cancer Treatment, Targeted Cancer Therapy.*

INTRODUCTION

Neoadjuvant and adjuvant therapies have become fundamental components of modern cancer treatment, significantly improving patient outcomes by enhancing the efficacy of surgical interventions. Neoadjuvant therapy, encompassing chemotherapy, radiation therapy, immunotherapy, and targeted therapy, is administered preoperatively to shrink tumors and increase the likelihood of successful surgical resection (Nevola, *et al*., 2023). Postoperative adjuvant therapy aims to eradicate residual cancer cells, minimizing recurrence and enhancing long-term survival. However, despite the success of these approaches, several challenges persist, including resistance to therapy, treatment-related toxicity, and the need for better predictive biomarkers to guide patient selection.

Submitted: July 25, 2024
Revised: February 03, 2025
Accepted: February 10, 2025

*Corresponding author: kiroloss.eskandar@gmail.com

The integration of these therapies with surgery marks a major evolution in cancer treatment over the past few decades, reflecting the growing importance of multimodal approaches. Technological advancements, such as precision surgery, robotic systems, and intraoperative imaging, have further improved surgical outcomes, while innovations in molecular-targeted therapies and immunotherapies have refined the management of microscopic disease (Li, *et al*., 2024). For instance, neoadjuvant treatments can often reduce tumor size sufficiently to enable less extensive surgery, preserving organ function and improving quality of life. Similarly, adjuvant therapies help manage any microscopic residual disease, significantly reducing relapse risks (Smith, *et al*., 2024). However, long-term side effects, such as immune-related adverse events from checkpoint inhibitors or chemotherapy-induced organ damage, highlight the need for careful patient monitoring and personalized treatment strategies.

As the field of oncology advances, the future of NAC and AC will likely be defined by tailoring treatment pathways based on tumor biology and patient-specific factors. The use of molecular profiling, circulating tumor DNA (ctDNA), and artificial intelligence-driven decision-making is paving the way for more precise, individualized treatment plans. This review provides a comprehensive analysis of the current landscape of neoadjuvant and adjuvant therapies, emphasizing the evolving role of personalized medicine and molecular oncology. By addressing the challenges and opportunities in optimizing treatment pathways, this review highlights the potential for targeted therapeutic innovations and enhanced surgical strategies to further improve cancer patient outcomes.

METHODOLOGY

This literature review followed a systematic approach, adhering to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines to ensure a transparent and reproducible selection process. The primary aim was to gather relevant articles and studies on neoadjuvant and adjuvant surgical interventions in oncology, focusing on advancements in surgery, drug development, multimodal therapy, and technological innovations. A comprehensive search was conducted across multiple reputable databases, including PubMed, Google Scholar, Scopus, and Web of Science, covering publications from 2010 to 2024 to capture both historical context and recent developments.

To ensure a thorough exploration of the topic, the following keywords were employed: "Neoadjuvant Therapy," "Adjuvant Surgery," "Surgical Oncology," "Multimodal Cancer Treatment," "Targeted Cancer Therapy," "Precision Medicine," and "Multidisciplinary Oncology."

Inclusion Criteria

Studies were included based on the following criteria:

- Publications in English.
- Studies specifically focused on oncology and surgical interventions.
- Research reporting on neoadjuvant and adjuvant therapies combined with surgical procedures, with an emphasis on their impact on cancer treatment pathways.
- Articles discussing advancements in multimodal therapies and their impact on patient outcomes, addressing both historical and modern perspectives (Conroy, *et al*., 2018; Forde, *et al*., 2022).

Indonesian Journal of Cancer Chemoprevention, October 2024
ISSN: 2088–0197
e-ISSN: 2355-8989

Study Selection Process

An initial search retrieved 137 articles. Given the broad scope of neoadjuvant and adjuvant therapies, an additional layer of specificity was applied during the screening process to focus on tumor-specific studies and clinically significant NAC and AC interventions. This targeted approach ensured a review that captures both broad trends and specific insights into evolving oncological practices.

After a thorough review process, 47 unique articles met the final inclusion criteria. Each article was evaluated by assessing titles, abstracts, and full texts for relevance to the objectives of the review. The selection process prioritized high-impact clinical trials, systematic reviews, and large-scale cohort studies, ensuring a robust and evidence-based discussion on optimizing NAC and AC pathways.

To further clarify the study selection process, a PRISMA flow diagram (Figure 1) is provided below, detailing the number of records identified, screened, and included, alongside reasons for exclusion at each stage. This approach ensures a comprehensive and systematic evaluation of the available literature, addressing both broad trends in multimodal cancer treatment and more specific neoadjuvant/adjuvant surgical interventions.



Figure 1. Illustrates the PRIMSA flow diagram.

HISTORICAL PERSPECTIVE

The evolution of neoadjuvant and adjuvant therapies in oncology reflects the growing understanding that surgery alone is often insufficient to achieve long-term survival, particularly for advanced cancers (Figure 2). Once the primary mode of treatment, surgical resection has been transformed by the integration of multimodal approaches, including chemotherapy, radiation, and immunotherapy, which have collectively revolutionized patient outcomes.

Adjuvant therapy emerged in the mid-20th century as a pivotal advancement, with early clinical trials in breast cancer using cyclophosphamide, methotrexate, and fluorouracil (CMF) in the 1970s demonstrating significant survival benefits (Veronesi, *et al*., 1977). This breakthrough paved the way for adjuvant therapies in a variety of cancers, including colorectal and gastric cancers,

showing the value of addressing microscopic residual disease (Siegel, *et al*., 2020). The broader development of drug therapies and innovations in molecular oncology established adjuvant therapy as a cornerstone of cancer care.

Neoadjuvant therapy, introduced later, aimed to improve surgical outcomes by shrinking tumors preoperatively. Its early success in rectal cancer, where chemotherapy and radiotherapy improved local control, demonstrated the value of reducing tumor size to enhance surgical resectability (Bosset, *et al*., 2006). Neoadjuvant chemotherapy in breast cancer also increased breast-conserving surgeries, showing its importance in reducing the need for radical procedures and optimizing patient outcomes (Hortobagyi, *et al*., 1988).

The evolution of these therapies is further amplified by technological advancements, such as targeted therapies and immunotherapies. For example, trastuzumab for HER2-positive breast cancer and pembrolizumab for melanoma have yielded significant survival improvements (Yu, *et al*., 2020; Thomas, *et al*., 2021), reflecting the shift toward precision medicine. In modern oncology, circulating tumor DNA (ctDNA) and other biomarkers have transformed neoadjuvant and adjuvant strategies by enabling better monitoring of minimal residual disease (MRD) and personalizing treatment adjustments (Menzies, *et al*., 2021).

As these therapies have evolved, so too have surgical techniques, such as minimally invasive procedures, which allow for more conservative but effective interventions. These advancements in both surgery and multimodal therapies have collectively reshaped cancer treatment, improving both survival and quality of life (Biesinger, *et al*., 2022).



Figure 2. This is a timeline showing drugs approved or indicated for the treatment of metastatic and non-metastatic non-small cell lung cancer (NSCLC) as of December 2020. When several approvals were made in a year, they are arranged chronologically from top to bottom. Adapted from ncbi.nlm.nih.gov (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9447511/figure/F1/).

Indonesian Journal of Cancer Chemoprevention, October 2024
ISSN: 2088–0197
e-ISSN: 2355-8989

NEOADJUVANT SURGICAL INTERVENTIONS

Neoadjuvant surgical interventions, performed after preoperative therapy, have transformed cancer treatment by improving the resectability of tumors and enhancing overall patient outcomes. These interventions focus on reducing tumor size, achieving better surgical margins, and lowering the risk of distant metastasis. By integrating surgery with neoadjuvant therapies, such as chemotherapy, radiation, and immunotherapy, this multimodal approach addresses both the primary tumor and micrometastatic disease, thus optimizing therapeutic outcomes.

One of the critical benefits of neoadjuvant interventions is tumor downstaging. By shrinking tumors preoperatively, previously inoperable tumors may become resectable, improving the chances of complete tumor removal and enhancing the patient's prognosis. Additionally, neoadjuvant therapies help improve the effectiveness of subsequent adjuvant treatments by reducing tumor burden and exposing residual cancer cells to systemic treatments like chemotherapy or radiation (Versluis, *et al*., 2020).

Multiple clinical trials and case studies have underscored the effectiveness of neoadjuvant approaches. For example, in breast cancer, neoadjuvant chemotherapy has increased the rates of breast-conserving surgeries, reducing the need for mastectomies and improving cosmetic outcomes (O'Donnell, *et al*., 2019). Similarly, in rectal cancer, preoperative chemoradiotherapy has led to significant improvements in local control and overall survival (Keung, *et al*., 2018). These cases highlight the role of neoadjuvant surgical interventions in enhancing patient outcomes while emphasizing the importance of personalized cancer care.



Figure 3. Mechanism of molecular action of N-acetylcysteine. Adapted from Aldini, *et al*. (2018) (https://pubmed.ncbi.nlm.nih.gov/29742938/).

The systemic benefits of neoadjuvant therapy extend beyond surgery (Figure 3). By addressing micrometastatic disease early, these therapies reduce the risk of recurrence and metastasis, significantly improving long-term survival rates (Siegel, *et al*., 2018). This holistic, multimodal approach to treatment sequencing, tailored to each patient's tumor characteristics and therapy response, represents a major shift in cancer care (Zeng, *et al*., 2018).

ADJUVANT SURGICAL INTERVENTIONS

Adjuvant surgical interventions play a pivotal role in reducing cancer recurrence by eliminating residual microscopic disease that remains post-surgery. These interventions enhance long-term survival and minimize metastasis risks, particularly in high-risk patients. Adjuvant therapies complement surgery by targeting undetected cancer cells, reducing recurrence and improving patient prognosis.

For example, in muscle-invasive bladder cancer (MIBC), adjuvant chemotherapy and immunotherapy following radical cystectomy have improved disease-free survival rates (Holzbeierlein, *et al*., 2024). Additionally, adjuvant precision surgery helps optimize patient outcomes by ensuring targeted removal of high-risk residual disease, minimizing the need for aggressive systemic therapies.

The integration of adjuvant molecular-targeted therapies has significantly advanced cancer treatment. In ALK-positive non-small cell lung cancer (NSCLC), the FDA-approved adjuvant therapy alectinib has outperformed traditional chemotherapy, nearly doubling disease-free survival post-resection (FDA Approves Alectinib for ALK-Positive Lung Cancer, 2024). These findings demonstrate how adjuvant therapy not only extends survival but also prevents early metastatic spread, reinforcing the importance of post-surgical interventions in high-risk molecular subtypes of cancer.

However, the effectiveness of adjuvant therapy is influenced by several real-world challenges, including therapy resistance, overtreatment concerns, and patient selection issues. In prostate cancer, the timing of adjuvant androgen-deprivation therapy (ADT) post-surgery remains debated, as early ADT can delay metastasis but may not always improve survival (Current Controversies in the Management of Biochemical Failure in Prostate Cancer, n.d.). Similarly, adjuvant treatment intensity must be carefully tailored to patient risk profiles, as some patients may achieve durable remission with surgery alone, avoiding unnecessary toxicity from additional systemic therapies. Future research should focus on identifying biomarkers that predict adjuvant therapy response, allowing for a more selective and individualized approach to postoperative cancer management.

COMBINATION OF NEOADJUVANT AND ADJUVANT APPROACHES

Combining neoadjuvant and adjuvant therapies with surgical interventions has emerged as a powerful strategy to maximize treatment efficacy by targeting both the primary tumor and micrometastatic disease. Neoadjuvant therapies aim to shrink tumors preoperatively, improving the likelihood of complete resection, while adjuvant therapies target any remaining microscopic disease postoperatively, reducing recurrence risk. This multimodal approach has demonstrated superior survival benefits across multiple cancer types.

One of the critical aspects of NAC+AC sequencing is tumor biology-driven treatment selection. In breast cancer, neoadjuvant chemotherapy allows for tumor downstaging, enabling breast-conserving surgery instead of mastectomy, preserving tissue and improving

quality of life (Globus, *et al*., 2023). Similarly, in rectal cancer, neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy has shown significant improvements in local control and recurrence reduction (Quezada-Diaz & Smith, 2022). The ability to integrate NAC and AC into a structured protocol enhances long-term survival while minimizing treatment morbidity.

Evidence from large-scale clinical trials further validates the NAC+AC approach. In NSCLC, the combination of neoadjuvant immunotherapy with surgery has demonstrated improved overall survival by inducing tumor regression and activating immune responses to residual disease (Kang, *et al*., 2021). Colorectal cancer patients treated with neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy experience a significant increase in 5-year survival rates (Smith, *et al*., 2024). Furthermore, in pancreatic cancer, the sequential use of NAC and AC has resulted in better resectability rates and prolonged disease-free survival compared to surgery-first approaches (Conroy, 2018).

Despite the advantages, several challenges must be addressed in optimizing NAC+AC treatment pathways. Patient selection remains a major hurdle, as not all cancers respond uniformly to neoadjuvant therapy, and over-treatment risks must be carefully considered. Additionally, the timing of surgery post-NAC is crucial, as delays beyond the optimal window can allow for tumor progression, potentially negating preoperative benefits. Moreover, the long-term impact of combining aggressive neoadjuvant and adjuvant regimens on patient quality of life requires further investigation, as cumulative toxicity may outweigh survival gains in some cases.

The future of NAC+AC therapy lies in precision oncology and adaptive treatment models. Molecular profiling, circulating tumor DNA (ctDNA) analysis, and artificial intelligence-driven decision algorithms are expected to enhance patient stratification and therapy customization, ensuring that each patient receives the most effective, least toxic multimodal approach tailored to their tumor's molecular characteristics. As research advances, the integration of real-world data and prospective clinical trials will be essential in refining NAC+AC sequencing, optimizing therapeutic efficacy while minimizing unnecessary treatment burden (Table 1).

Table 1 Summary of neoadjuvant (NAC), adjuvant (AC), and combined (NAC+AC) chemotherapy in oncology—study designs, cancer types, patient outcomes, and limitations.

Study Design	Patient Population/ Cancer Type	Summary of Patient Outcomes	Limitations/Challenges
RCT (Forde, *et al*., 2022 - CheckMate 816 Trial)	Non-Small Cell Lung Cancer (NSCLC)	NAC + Immunotherapy improved pathological complete response and overall survival.	Requires biomarkers for patient selection; long-term survival data pending.
RCT (Schmid, *et al*., 2022 - KEYNOTE-522 Trial)	Triple-Negative Breast Cancer (TNBC)	NAC + Pembrolizumab led to higher pathological complete response and reduced recurrence.	High immune-related adverse effects.
Meta-Analysis (Versluis, *et al*., 2020)	Melanoma (Neoadjuvant checkpoint blockade)	Improved overall survival with NAC immunotherapy vs. AC alone.	Risk of immune-related toxicity and patient selection issues.
RCT (Holzbeierlein, *et al*., 2024 - MIBC)	Muscle-Invasive Bladder Cancer (MIBC)	AC (nivolumab) improved disease-free survival post-cystectomy.	High cost; long-term efficacy vs. chemotherapy debated.
Observational Study (Smith, *et al*., 2024)	Colorectal Cancer	NAC followed by surgery and AC improved survival and reduced recurrence.	Heterogeneity in patient selection and therapy sequencing.
RCT (Conroy, *et al*., 2018 - Pancreatic Cancer Study)	Locally Advanced Pancreatic Cancer	NAC downstaged tumors, improving surgical resectability; AC improved systemic control.	Limited by chemotherapy resistance and high recurrence rates.
Cohort Study (Quezada-Diaz & Smith, 2022)	Rectal Cancer	NAC + Chemoradiotherapy improved local control and resectability.	Variability in radiation response and long-term toxicities.

INNOVATIVE TECHNIQUES IN ONCOLOGICAL SURGERY

Recent advances in oncological surgery have significantly enhanced the precision and efficacy of both neoadjuvant and adjuvant interventions, helping improve patient outcomes. One of the most notable developments is the widespread use of minimally invasive surgery (MIS) and robotic-assisted techniques. These innovations reduce postoperative complications by minimizing muscle damage, blood loss, and recovery times. Robotic-assisted surgeries, such as those performed with the da Vinci Surgical System, offer surgeons greater precision, dexterity, and control, particularly in complex oncological procedures (Minimally Invasive Surgery | Methodist Healthcare, n.d.).

MIS techniques, including laparoscopic and thoracoscopic surgeries, are now standard for cancers of the gastrointestinal tract, lungs, and gynecological systems. These methods provide several benefits, such as reduced postoperative pain, faster recovery, and shorter hospital stays. For example, robotic-assisted surgeries allow for more accurate dissections and anastomoses, improving outcomes in colorectal and gynecological cancers (Methodist Healthcare, 2024; Laina, *et al*., 2017).

Advances in imaging and navigation technologies have further refined surgical precision. Intraoperative imaging techniques, such as MRI and CT scans, enable surgeons to visualize tumors and critical structures in real-time, minimizing damage to healthy tissue. These image-guided techniques are especially beneficial in delicate procedures, such as brain and liver surgeries, where precision is paramount. Additionally, augmented reality (AR) and virtual reality (VR) technologies are being integrated into surgical practice, enabling surgeons to superimpose digital images onto the surgical field for enhanced spatial awareness and accuracy (Shen, *et al*., 2019).

A breakthrough in precision surgery involves the use of genomic and molecular profiling to tailor surgical plans and adjunct therapies to individual tumor characteristics. Fluorescence-guided surgery (FGS), where cancer cells are made to glow under specific lights, is an example of how technology is helping surgeons achieve more complete resections, reducing residual disease and improving long-term outcomes (Nema & Vachhani, 2022). These innovations underscore the shift towards more personalized surgical care, where treatments are specifically tailored to each patient's unique tumor biology.

Robotic systems incorporating artificial intelligence (AI) are also transforming surgical oncology. AI-driven systems assist with tasks such as autonomous camera positioning, instrument tracking, and even performing certain procedures autonomously. These innovations reduce the cognitive load on surgeons, allowing for more consistent and efficient surgeries. For example, AI has been successfully employed in autonomous suturing and anastomosis, improving the speed and accuracy of these tasks (Miao, *et al*., 2017; Feng, *et al*., 2017).

The integration of these innovative techniques into oncological surgery represents a significant leap forward, promising better outcomes for cancer patients through enhanced precision, reduced complications, and quicker recovery times. These advancements, when combined with neoadjuvant and adjuvant therapies, create a comprehensive, multimodal approach to cancer care that maximizes therapeutic benefit.

CHALLENGES AND CONSIDERATIONS

While technological advancements in oncological surgery have improved patient outcomes, several challenges persist, particularly in the context of integrating multimodal therapies. Minimally invasive and robotic-assisted surgeries have transformed the surgical landscape by reducing postoperative pain, shortening hospital stays, and expediting recovery times. However,

these techniques require extensive training and can be cost-prohibitive, limiting accessibility in certain settings. Additionally, despite their benefits, the increased reliance on technology introduces new potential complications, such as system malfunctions or the need for surgeon expertise in handling complex robotic systems (Negrut, *et al*., 2024).

The integration of advanced imaging and navigation technologies, while improving surgical precision, presents its own set of challenges. High-resolution imaging techniques like MRI and CT scans, when combined with intraoperative navigation, enhance the surgeon's ability to locate tumors and assess margins accurately. However, the availability and cost of these technologies can restrict their use, particularly in resource-limited environments, further complicating the adoption of precision surgical approaches (Caruso, *et al*., 2023).

Moreover, the rise of precision surgery, which tailors interventions based on molecular and genetic tumor profiles, holds great promise for improving outcomes. However, it also raises concerns about over-treatment and cost-effectiveness. While precision surgery has been shown to improve survival and reduce recurrence, it requires sophisticated diagnostic tools and multidisciplinary collaboration, adding layers of complexity to cancer care. This approach also necessitates careful planning to avoid overtreatment, particularly in patients with indolent cancers, where aggressive surgical interventions may not significantly improve outcomes (Sanglier, *et al*., 2022).

Postoperative management, especially acute pain management, remains a significant challenge. Effective pain management is critical to preventing long-term complications, such as persistent postsurgical pain, which can negatively affect recovery and increase healthcare costs (Small & Laycock, 2020). The timing and sequencing of neoadjuvant and adjuvant therapies with surgical interventions also require careful consideration to ensure the maximal therapeutic benefit while minimizing adverse effects.

Additionally, patient-specific factors, such as comorbidities and genetic predispositions, are essential to consider when planning surgical interventions. Personalized treatment strategies that account for these factors can help mitigate risks and improve outcomes. For example, patients with preexisting conditions may require tailored perioperative care protocols and individualized pain management strategies to optimize recovery and minimize complications (Khazov, *et al*., 2021). Accessibility to advanced care is another challenge in resource-limited settings, where innovations may not be as readily available, limiting the potential benefits of advanced multimodal therapies.

CASE STUDIES AND CLINICAL TRIALS

The efficacy of integrating neoadjuvant and adjuvant surgical interventions is best demonstrated through large-scale clinical trials and illustrative case studies, which provide critical evidence supporting the strategic application of these treatments in oncology. These examples showcase how the multimodal approach combining surgery with systemic therapies can significantly improve patient outcomes.

Clinical trials are essential in establishing optimal treatment protocols for neoadjuvant and adjuvant therapies. For instance, the KEY-NOTE-522 trial demonstrated the significant benefit of combining pembrolizumab with chemotherapy for triple-negative breast cancer, showing improved pathological complete response rates (Schmid, *et al*., 2022). Similarly, the CheckMate 816 trial highlighted the value of neoadjuvant nivolumab combined with chemotherapy in resectable non-small cell lung cancer (NSCLC), leading to improved event-free survival (Forde, *et al*., 2022). These trials underscore the importance of integrating immunotherapy and chemotherapy in enhancing outcomes, particularly for cancers with limited surgical options, while optimizing the sequencing of multimodal therapies.



Figure 4. Schematic of a future neoadjuvant biomarker-driven clinical trial for LAGC. Patients with resectable, locally advanced, GC/GEJC will be stratified into cohorts based on biomarkers: HER2+, MSI-H, biomarker X, biomarker Y, or none of the above. Biomarker X and Y are placeholders for current (such as FGFR or CLDN 18.2) or future biomarkers of clinical interest in LAGC. Each biomarker cohort will have two differing treatment arms based on data from prior clinical trials. Patients will undergo combination neoadjuvant chemotherapy, immunotherapy, and/or biomarker-directed treatment for 4–6 months and then undergo surgical resection followed by adjuvant therapy based on their cohort. The primary outcome is the achievement of 30% pCR. IO = immuno-oncology therapy. Chemo = chemotherapy. Adapted from mdbi.com (https://www.mdpi.com/cancers/cancers-15-04114/article_deploy/html/images/cancers-15-04114-g001.png).

Case studies offer further insight into the practical application of these strategies. For example, the use of neoadjuvant chemoradiation in rectal cancer has been shown to downstage tumors, facilitating sphincter-preserving surgeries and improving quality of life outcomes (Glynne-Jones, *et al*., 2017). Similarly, in esophageal cancer, neoadjuvant chemotherapy significantly improved both resectability and survival rates, underscoring its value in treatment protocols for difficult-to-treat cancers (Shapiro, *et al*., 2015). These examples highlight how combining systemic therapies with surgery can optimize patient outcomes, improve resectability, and minimize the need for more extensive surgical interventions.

These case studies and trials underscore the importance of evidence-based, individualized approaches to neoadjuvant and adjuvant treatments. The success of these strategies depends on rigorous clinical research, multidisciplinary collaboration, and personalized treatment planning to maximize patient outcomes, reduce recurrence, and enhance quality of life. As technological advancements in surgery continue to evolve, the combination of innovative surgical techniques with neoadjuvant and adjuvant therapies is likely to further refine and improve treatment protocols.

FUTURE DIRECTIONS IN NEOADJUVANT AND ADJUVANT SURGICAL ONCOLOGY

The future of neoadjuvant and adjuvant surgical oncology is being shaped by cutting-edge research and technological innovations. Central to this evolution is the rise of personalized medicine, particularly through the use of genomic

profiling to tailor treatment strategies to the unique characteristics of each patient's cancer. This represents a continuation of the shift toward more individualized care that has been a hallmark of recent advancements in oncology (Liu, *et al*., 2024).

Recent studies highlight the potential of combining traditional therapies with novel agents, such as immune checkpoint inhibitors. For example, the KEYNOTE-811 trial showcased the efficacy of dual PD-1 and HER2 blockade in HER2-positive gastric cancer, marking a promising step toward more effective treatment regimens (Janjigian, *et al*., 2021) (Figure 4). Additionally, ongoing clinical trials are investigating combinations of chemotherapy, targeted therapies, and immunotherapies in the neoadjuvant setting, with the goal of improving pathological complete response rates and extending long-term survival (Forde, *et al*., 2018; Min, *et al*., 2022).

Genomic profiling and personalized medicine are increasingly central to developing these therapies. With advances in liquid biopsies and circulating tumor DNA (ctDNA) analyses, clinicians can monitor treatment response and detect minimal residual disease with greater precision. These technologies hold the potential to guide personalized postoperative treatments, ensuring a more adaptive and effective approach to cancer care (DeMichele, *et al*., 2015; Liu, *et al*., 2021). As molecular oncology continues to advance, these innovations will allow for more precise targeting of residual disease, improving outcomes while minimizing unnecessary treatment.

On the surgical front, innovations such as minimally invasive and robotic-assisted surgeries continue to improve the precision and safety of oncological procedures. These techniques reduce recovery times and complications while enhancing the accuracy of tumor resections. In addition, advancements in intraoperative imaging including real-time MRI and CT scans have improved tumor localization, contributing to better surgical outcomes (Janjigian, *et al*., 2021; Liu, *et al*., 2021).

The future of neoadjuvant and adjuvant therapies lies in the continued integration of technological advancements with precision medicine. The ongoing development of tools such as AI-driven robotic systems, real-time imaging, and molecular profiling will allow for more refined and personalized surgical strategies. Precision surgery, in particular, offers the potential to optimize outcomes through a combination of detailed preoperative planning and real-time intraoperative guidance, leading to more effective, less invasive treatments tailored to each patient's tumor biology.

CONLUSION

In conclusion, the integration of neoadjuvant and adjuvant surgical interventions has revolutionized cancer care, offering enhanced tumor control and improved patient outcomes. By combining systemic therapies with surgical innovations, oncologists have been able to downstage tumors, improve resectability, and extend survival rates across various cancer types. The combination of historical milestones with contemporary advancements in minimally invasive and robotic-assisted surgeries, advanced imaging technologies, and personalized medicine has pushed the boundaries of what is achievable in oncological surgery.

Looking ahead, future advancements will likely focus on increasing precision in treatment through genomic profiling and personalized medicine. This approach holds the promise of tailoring neoadjuvant and adjuvant therapies to the specific characteristics of each patient's cancer, thereby maximizing therapeutic efficacy and minimizing side effects. As research continues to evolve, the synergy between neoadjuvant and adjuvant therapies, coupled with advanced surgical techniques, is expected to further enhance both quality of life and survival rates for cancer patients.

Ultimately, the ongoing integration of innovative therapies, cutting-edge technologies, and personalized treatment approaches will play a pivotal role in shaping the future of oncological care. This multimodal approach offers new hope and opportunities for improved cancer treatment outcomes, ensuring that patients receive the most effective, tailored care possible in the rapidly evolving field of oncology.

REFERENCES

Biesinger, M., Eicken, N., Varga, A., Weber, M., Brndiar, M., Erd, G., *et al.*, 2022, Lymph but Not Blood Vessel Invasion Is Independent Prognostic in Lung Cancer Patients Treated by VATS-Lobectomy and Might Represent a Future Upstaging Factor for Early Stages, *Cancers*, **14**(8), 1893.

Bosset, J.F., Collette, L., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., *et al.*, 2006, Chemotherapy with preoperative radiotherapy in rectal cancer, *The New England Journal of Medicine*, **355**(11), 1114–1123.

Caruso, M., Stanzione, A., Prinster, A., Pizzuti, L. M., Brunetti, A., Maurea, S., and Mainenti, P.P., 2023, Role of advanced imaging techniques in the evaluation of oncological therapies in patients with colorectal liver metastases, *World Journal of Gastroenterology*, **29**(3), 521–535.

Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A.C., Raoul, J.L., *et al.*, 2018, FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer, *The New England Journal of Medicine*, **379**(25), 2395–2406.

Current Controversies in the Management of Biochemical Failure in Prostate Cancer, 2012, Hematology & Oncology, November. Available at: https://www.hematologyandoncology.net/archives/november-2012/current-controversies-in-the-management-of-biochemical-failure-in-prostate-cancer/ (Accessed 3 February 2025).

DeMichele, A., Yee, D., Berry, D.A., Albain, K.S., Benz, C.C., Boughey, J., *et al.*, 2015, The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer, *Clinical Cancer Research*, **21**(13), 2911–2915.

Feng, X., Yang, J., Laine, A.F., and Angelini, E.D., 2017, Discriminative Localization in CNNs for Weakly-Supervised Segmentation of Pulmonary Nodules, *Lecture Notes in Computer Science*, 568–576.

Forde, P.M., Chaft, J.E., Smith, K.N., Anagnostou, V., Cottrell, T.R., Hellmann, M.D., *et al.*, 2018, Neoadjuvant PD-1 Blockade in Resectable Lung Cancer, *New England Journal of Medicine/The New England Journal of Medicine*, **378**(21), 1976–1986.

Forde, P.M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M.M., *et al.*, 2022, Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer, *The New England Journal of Medicine*, **386**(21), 1973–1985.

Globus, O., Greenhouse, I., Sella, T., and Gal-Yam, E.N., 2023, The neoadjuvant systemic treatment of early breast cancer: a narrative review, *Annals of Breast Surgery*, **7**, 39.

Glynne-Jones, R., Wyrwicz, L., Tiret, E., Brown, G., Rödel, C., Cervantes, A., *et al.*, 2017, Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, *Annals of oncology : official journal of the European Society for Medical Oncology*, **28**(suppl_4), iv22–iv40.

Holzbeierlein, J., Bixler, B.R., Buckley, D.I., Chang, S.S., Holmes, R.S., James, A.C., *et al.*, 2024, Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024), *The Journal of urology*, **212**(1), 3–10.

Hortobagyi, G.N., Ames, F.C., Buzdar, A.U., Kau, S.W., McNeese, M.D., Paulus, D., *et al.*, 1988, Management of stage III primary breast cancer with primary chemotherapy, surgery, and

radiation therapy, *Cancer*, **62**(12), 2507–2516.

IEEE Robotics and Automation Letters publication information, 2019, *IEEE Robotics & Automation Letters*, **4**(4), C2.

Janjigian, Y.Y., Kawazoe, A., Yañez, P., Li, N., Lonardi, S., Kolesnik, O., *et al.*, 2021, The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer, *Nature*, **600**(7890), 727–730.

Kang, J., Zhang, C., and Zhong, W.Z., 2021, Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art, *Cancer communications (London, England)*, **41**(4), 287–302.

Keung, E.Z., Ukponmwan, E.U., Cogdill, A.P., and Wargo, J.A., 2018, The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies, *Annals of surgical oncology*, **25**(7), 1814–1827.

Khazov, P.A., Maystrenko, A.D., Gurschenkov, A.V., and Shvarts, E.Y., 2021, Open-heart surgery in elderly patients: short-term vs. long-term effects, *Saratov Medical Journal*, **2**(4), e0405

Laina, I., Rieke, N., Rupprecht, C., Vizcaíno, J.P., Eslami, A., Tombari, F. and Navab, N., 2017, Concurrent Segmentation and Localization for Tracking of Surgical Instruments, arXiv preprint arXiv:1703.10701. Available at: https://arxiv.org/abs/1703.10701 (Accessed: 3 February 2025).

Li, J., Tang, T., Zong, H., Wu, E., Zhao, J., Wu, R., *et al.*, 2024, Intelligent medicine in focus: the 5 stages of evolution in robot-assisted surgery for prostate cancer in the past 20 years and future implications, *Military Medical Research*, **11**(1), 58.

Lim, J., Auerbach, M., MacLean, B., Al-Sharea, A., and Richards, T., 2023, Intravenous Iron Therapy to Treat Anemia in Oncology: A Mapping Review of Randomized Controlled Trials, *Current oncology (Toronto, Ont.)*, **30**(9), 7836–7851.

Liu, B., Zhou, H., Tan, L., Siu, K.T.H., and Guan, X., 2024, Exploring treatment options in cancer: Tumor treatment strategies, *Signal Transduction and Targeted Therapy*, **9**(1), 175.

Liu, J., Blake, S.J., Yong, M.C., Harjunpää, H., Ngiow, S.F., Takeda, K., *et al.*, 2016, Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease, *Cancer discovery*, **6**(12), 1382–1399.

Menzies, A.M., Scolyer, R.A., and Long, G.V., 2021, Neoadjuvant Immunotherapy in Melanoma-The New Frontier, *Clinical cancer research: an official journal of the American Association for Cancer Research*, **27**(15), 4133–4135.

Methodist Healthcare (n.d.), Minimally Invasive Surgery, Available at: https://www.sahealth.com/specialties/surgery/minimally-invasive-surgery (Accessed: 3 February 2025).

Miao, S., Piat, S., Fischer, P., Tuysuzoglu, A., Mewes, P., Mansi, T., and Liao, R., 2017, Dilated FCN for Multi-Agent 2D/3D Medical Image Registration, arXiv preprint arXiv:1712.01651. Available at: https://arxiv.org/abs/1712.01651 (Accessed: 3 February 2025).

Min, L., Liu, N., Zhou, Y., and Niu, Z., 2022, 1220P Efficacy and safety of camrelizumab combined with FLOT versus FLOT alone as neoadjuvant therapy in patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy, *Annals of Oncology*, **33**, S1106.

National Cancer Institute, 2024, FDA Approves Alectinib for ALK-Positive Lung Cancer, Cancer.gov, 8 May. Available at: https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-alectinib-lung-cancer-alk-positive (Accessed: 3 February 2025).

Negrut, R.L., Cote, A., Caus, V.A. and Maghiar, A.M., 2024, Systematic Review and Meta-Analysis of Laparoscopic versus Robotic-Assisted Surgery for Colon Cancer: Efficacy, Safety, and Outcomes—A Focus on Studies from 2020–2024, *Cancers*, **16**(8), 1552.

Nema, S., and Vachhani, L., 2022, Surgical instrument detection and tracking technologies: Automating

dataset labeling for surgical skill assessment, *Frontiers in Robotics and AI*, **9**.

Nevola, R., Delle Femine, A., Rosato, V., Kondili, L.A., Alfano, M., Mastrocinque, D., *et al.*, 2023, Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?, *Cancers*, **15**(11), 2950.

O'Donnell, J.S., Hoefsmit, E.P., Smyth, M.J., Blank, C.U., and Teng, M.W.L., 2019, The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment, *Clinical cancer research : an official journal of the American Association for Cancer Research*, **25**(19), 5743–5751.

Quezada-Diaz, F.F., and Smith, J.J., 2022, Neoadjuvant Therapy for Rectal Cancer, *Surgical oncology clinics of North America*, **31**(2), 279–291.

Sanglier, T., Ross, R., Klein-Panneton, K., Poppe, R., Antao, V., Mamounas, E.P., and Cain, H., 2022, The impact of neoadjuvant treatment (NAT) on surgery in early breast cancer (EBC): A real-world data study, *Journal of Clinical Oncology*, **40**(16_suppl), e12609.

Schmid, P., Cortes, J., Dent, R., Pusztai, L., Mcarthur, H., Kümmel, S., *et al.*, 2022, Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer, *New England Journal of Medicine/the New England Journal of Medicine*, **386**(6), 556–567.

Shapiro, J., van Lanschot, J.J.B., Hulshof, M.C.C.M., van Hagen, P., van Berge Henegouwen, M.I., Wijnhoven, B.P.L., *et al.*, 2015, Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial, *The Lancet. Oncology*, **16**(9), 1090–1098.

Shen, Z., Han, X., Xu, Z., and Niethammer, M. 2019, Networks for Joint Affine and Non-parametric Image Registration, *arXiv.org*. https://arxiv.org/abs/1903.08811

Siegel, R.L., Miller, K.D., and Jemal, A., 2018, Cancer statistics, 2018, *CA: a cancer journal for clinicians*, **68**(1), 7–30.

Siegel, R.L., Miller, K.D., and Jemal, A., 2020, Cancer statistics, 2020, *CA: a cancer journal for clinicians*, **70**(1), 7–30.

Small, C., and Laycock, H., 2020, Acute postoperative pain management, *British Journal of Surgery*, **107**(2), e70–e80.

Smith, H.G., Nilsson, P.J., Shogan, B.D., Harji, D., Gambacorta, M.A., Romano, A., *et al.*, 2024, Neoadjuvant treatment of colorectal cancer: comprehensive review, *BJS Open*, **8**(3), zrae038.

Thomas, D., and Bello, D.M., 2021, Adjuvant immunotherapy for melanoma, *Journal of surgical oncology*, **123**(3), 789–797.

Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., *et al.*, 2002, Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer, *The New England journal of medicine*, **347**(16), 1227–1232.

Versluis, J.M., Long, G.V., and Blank, C.U., 2020, Learning from clinical trials of neoadjuvant checkpoint blockade, *Nature medicine*, **26**(4), 475–484.

Wu, Y.L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., *et al.*, 2020, Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer, *The New England journal of medicine*, **383**(18), 1711–1723.

Yu, J.X., Hodge, J.P., Oliva, C., Neftelinov, S.T., Hubbard-Lucey, V.M., and Tang, J., 2019, Trends in clinical development for PD-1/PD-L1 inhibitors, *Nature Reviews. Drug Discover/Nature Reviews. Drug Discovery*, **19**(3), 163–164.

Zeng, H., Chen, W., Zheng, R., Zhang, S., Ji, J.S., Zou, X., *et al.*, 2018, Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries, *The Lancet. Global health*, **6**(5), e555–e567.